Interleukin-6 (Il-6) is an established risk factor for inferior oncological outcomes of HNSCC patients, and Il-6 has been demonstrated to be associated with HNSCC progression, angiogenesis and metastasis [50]. The gene discussed is IL6; the disease is head and neck squamous cell carcinoma.